IMVTImmunovant

Median target
$50
calls from the last 12 months
Implied return
+32.8%
median target vs. price
Coverage
15 analysts · 16 calls
updated in the last 12 months
Consensus
13/2/0+13 net
Buy / Hold / Sell

Which analysts are behind IMVT's consensus?

See every current rating, price target and the analysts' track records for Immunovant — plus the full analyst rankings, firm analytics and screener.

The consensus above reflects 15 analysts with calls on IMVT updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

IMVT elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-08-28InsidersPande AtulDirectorInsider sale1.5K sh @ $43.27 · planned trade$65K
2026-08-20InsidersGloria MelanieChief Operating OfficerInsider sale3.1K sh @ $44.16$135K
2026-07-24InsidersPande AtulDirectorInsider sale1.5K sh @ $39.80 · planned trade$60K
2026-07-23InsidersGirao TiagoChief Financial OfficerInsider sale6.8K sh @ $38.69$263K
2026-07-23InsidersStout Jay SChief Technology OfficerInsider sale2.9K sh @ $38.69$111K
2025-03-05ExecutiveTrump, Donald JPresidentPurchaseIMMUNOVANT INC$15,001 - $500,003

More: insider activity · executive branch · trending